Strong Q1 prompts an improved guidance
05/05/21 -"2021 started on a high as Novo reported robust growth, despite ‘tough comps’, i.e. forward buying-driven Q1 20. Moreover, as management expects this momentum to be maintained, the 2021 outlook has ..."
Pages
65
Language
English
Published on
05/05/21
You may also be interested by these reports :
13/08/26
PolyPeptide released its already-known results, with no surprises. There was strong operational performance, with guidance raised for FY26. The focus ...
13/08/26
The Q2 results surpassed expectations, backed by the unrelenting growth of Dupixent and the impressive uptake of some newly launched medicines. ...
12/08/26
With the Astra-BMS merger idea likely being shelved after apprehensions raised by various analysts/investors, we re-float the idea of an Astra-GSK ...
04/08/26
Imagine a restaurant having to serve its customers by ordering outside food. We cannot resist drawing parallels between this hypothetical scenario ...